

**Vaxon-Biotech to Present Latest Clinical and
Immunological Data
of its Vx-001 Cancer Vaccine
at the AACR 99th Annual Meeting**

**P
R
E
S
S

R
E
L
E
A
S
E**

Evry-Genopole, France, April 11, 2008 – Vaxon-Biotech announces that most recent clinical and immunological data from the Vx-001 cancer vaccine trial will be presented in the Clinical Immunotherapy Minisymposium at the AACR 99th Annual Meeting. The meeting will take place in San Diego CA, April 12-16, 2008.

About Vaxon-Biotech

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of cancer. The first two products under development, Vx-001 and Vx-006, are novel treatments for solid tumors. For more information, go to www.vaxon-biotech.com.

Contacts

Kostas Kosmatopoulos, MD, PhD
CSO
kkosmatopoulos@vaxon-biotech.com